| Document |
Document Title |
|
WO2002022776A9 |
The present invention relates to novel human coagulation Factor VIIa variants having coagulant activity as well as nucleic acid constructs encoding such variants, vectors and host cells comprising and expressing the nucleic acid, pharmac...
|
|
WO/2003/039580A1 |
The present invention relates to a composition comprising factor VII or a factor VII-related polypeptide, and PAI-1 or a PAI-1-related polypeptide, and the use thereof for treating bleeding episodes.
|
|
WO/2003/040098A1 |
Compounds of the formula (I), useful as metalloproteinase inhibitors, especially as inhibitors of MMP12.
|
|
WO/2003/039585A1 |
The present invention relates to a composition comprising factor VII or a factor VII-related polypeptide and a protein C inhibitor, and the use thereof for treating bleeding episodes.
|
|
WO/2003/035099A1 |
The present invention encompasses pharmaceutical formulations comprising a biphasic mixture which comprises a glucagon like peptide (GLP-1) compound in a solid phase and an insulin in a solution phase.
|
|
WO/2003/030876A1 |
Orally disintegrating valdecoxib fast-melt tablets and processes for preparing such dosage forms are provided. The compositions are useful in treatment or prophylaxis of cycloosygenase-2 mediated conditions and disorders.
|
|
WO2002020619A9 |
The invention described herein provides for human antibodies produced in non-human animals that specifically bind to Pseudomonas aeruginosa Lipopolysaccharide (LPS). The invention further provides methods for making the antibodies in a n...
|
|
WO/2003/030905A1 |
A compound represented by the formula (I): wherein R1 and R4 each independently is alkyl or alkoxy&semi R2 and R3 each independently is hydrogen or alkyl&semi R5 is hydrogen or halogeno&semi R6 is hydrogen or hydroxy&semi and X1 and X2 e...
|
|
WO/2003/028741A1 |
Composition of Hypochlorous acid characterized because it has the following chemical composition, Hypochlorous acid 6,5 7,3%; Chlorhydric acid 27,6 28,5%; Sodium chloride 13,6 14,2%; Sodium hypochlorite 34,8 35,4%; Chlorine in solution 7...
|
|
WO2002022166A9 |
The present invention relates to methods of modulating angiogenesis and inhibiting tumor progression by using TWEAK receptor (Fn14) agonists. In particular, methods for inhibiting angiogenesis are disclosed.
|
|
WO/2003/027102A1 |
The present invention relates to organic of general formula (I), capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
|
|
WO/2003/026744A1 |
A method of use is disclosed for preventing or retarding posterior capsular opacification or scar formation following ophthalmic surgery by treatment of the surgical site with epothilones and analogs thereof.
|
|
WO/2003/026711A1 |
The inventive polyfunctional biocompatible hydrogel comprises 1.3-15 mass % of acrylamide, 0-004-0.975 mass % of cross-linking agents- N,N'-methylen-bis-acrylamide, 0.004-5.1 mass % of N,N'-ethylen-bis-acrylamide, 0.002-0.45 mass % of po...
|
|
WO2002094019A9 |
The invention provides compositions containing a highly purified antiendotoxin compound and methods of preparing and using such compositions.
|
|
WO/2003/018033A1 |
Compositions, methods and the like comprising fucans such as fucoidan to treat surgical adhesions, arthritis, and psoriasis.
|
|
WO/2003/018756A2 |
The invention provides purified preparations of prostaglandin E synthase (PGES), analogs and variants thereof, such as portions thereof, and fusion polypeptides comprising these. The invention also provides methods for obtaining these pu...
|
|
WO/2003/015768A2 |
The present invention discloses a method for the modulation of the enzymatic activity of prolyl endopeptidase in various human tissues and their biological effect on intracellular inositol (1,4,5) triphosphate concentration. The present ...
|
|
WO/2003/015799A1 |
A method of treating, preventing, or inhibiting pain, inflammation or inflammation-associated disorder in a subject in need of such treatment or prevention provides for treating the subject with chondroitin sulfate and a cyclooxygenase-2...
|
|
WO/2003/013477A1 |
Polymeric compositions containing a high percentage of bound polypropylene glycol provide matrices for the controlled release of drugs and medicinal agents. The compositions are prepared by the polymerization of ethylenically unsaturated...
|
|
WO/2003/012111A2 |
A conjugate comprising first and second sequence wherein the first sequence comprises a polypeptide which is capable of binding to antigen presenting cell (APC) and the second sequence is a polypeptide comprising a modulator of the Notch...
|
|
WO/2003/011313A1 |
The present invention relates to a pharmaceutical composition comprising as an effective ingredient an oligopeptide identical or analagous to the C-terminal portion of OGP, having stimulatory activity on the production of hematopoietic c...
|
|
WO/2003/008444A2 |
The present invention relates to peptides, compositions, and methods of treating conditions requiring removal or destruction of harmful or unwanted cells in a patient, such as benign and malignant tumors, using proteins (and peptides der...
|
|
WO/2003/008443A2 |
The present invention is directed to methods of treating conditions requiring removal or destruction of harmful or unwanted cells in a patient, such as benign and malignant tumors, using compounds containing or based on peptides comprisi...
|
|
WO/2003/007686A2 |
The present invention is based on the unexpected discovery that activated protein C (APC) is inactivated by copper. Accordingly, the invention provides improved methods of treating diseases and conditions treatable with APC which utilize...
|
|
WO/2003/008374A1 |
This invention is directed to novel oxamyl dipeptide ICE/ced-3 family inhibitor compounds having the following structure (I), wherein A, B, R, R¿1?, R¿1? p and q are as defined herein. The invention is also directed to pharmaceutical c...
|
|
WO/2003/007954A2 |
The invention is directed to sulfonyl aromatic hydroxamic acid compounds and salts thereof that, inter alia, inhibit matrix metalloprotease (MMP) activity and/or aggrecanase activity. In some particularly preferred embodiments, the compo...
|
|
WO/2003/004098A1 |
The present invention provides a composition for topical administration comprising an interleukin 2 inhibitor and an antimicrobial agent as active ingredients thereof, wherein said interleukin 2 inhibitor contains a tricyclo compound as ...
|
|
WO2001079480A9 |
The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells tran...
|
|
WO2001057267A9 |
The invention provides novel polynucleotides and polypeptides encoded by such polynucleotides and mutants or variants thereof that correspond to a novel human secreted CUB domain polypeptide. These polynucleotides comprise nucleic acid s...
|
|
WO2001055336A9 |
The invention provides novel polynucleotides and polypeptides encoded by such polynucleotides and mutants or variants thereof that correspond to a novel human secreted CD84-like polypeptide. These polynucleotides comprise nucleic acid se...
|
|
WO/2003/000344A1 |
A surface active phospholipid (SAPL) composiiton in the form of a solution, dispersed or especially a paste comprising DPPC (dipalmitoyl-phospatidyl-choline) is used to reduce the risk of adhesions after surgery, especially open surgery ...
|
|
WO/2002/102428A1 |
It is intended to provide a synechia inhibitory material which is excellent in biocompatibility and bioabsorbability and has a favorable strength in suture and adhesion. A synechia inhibitory material composed of a gelatin film 11 and a ...
|
|
WO/2002/096366A2 |
Metallotetrapyrrolic compounds having photherapeutics properties useful in photodetection and phototherapy of target issues, particularly porphyrins and azaporphyrins that including gallium in the central pyrrolic core. Also disclosed ar...
|
|
WO/2002/097030A2 |
The present invention is directed to methods of treating conditions requiring removal or destruction of harmful or unwanted cells in a patient, such as benign and malignant tumors, using peptides derived from the amino acid sequences of ...
|
|
WO/2002/092016A2 |
Provided herein are methods of treating various medical conditions that require the formation of new bone by administering an effective amount of a RANK antagonist. Antagonists suitable for use in the subject methods include soluble RANK...
|
|
WO/2002/092075A2 |
Metal carbonyls are used to deliver CO having biological activity, for example for stimulating neurotransmission or vasodilation, or for the treatment of any of hypertension, radiation damage, endotoxic shock, inflammation, and inflammat...
|
|
WO/2002/089807A1 |
This invention is directed to methods of providing cardioprotection in a patient in need thereof comprising administering to said patient a pharmaceutically effective amount of a compound having adenosine A1/A2 agonistic activity, or a p...
|
|
WO/2002/090530A2 |
The invention provides human kinases and phosphatases (KPP) and polynucleotides which identify and encode KPP. The invention also provides expression vector, host cells, antibodies, agonists, and antagonists. The invention also provides ...
|
|
WO/2002/088095A1 |
The present invention provides compounds of formula (I) including stereoisomers, prodrugs and pharmaceutically acceptable salts or solvates thereof wherein the variables are as defined in the description, processes for their preparation,...
|
|
WO/2002/085899A1 |
The present invention relates to novel classes of compounds of formula (I) which are caspase and TNF-alpha inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutica...
|
|
WO/2002/085940A2 |
The present invention relates to new polynucleotides deriving from the nucleotide sequence of the EPO gene and comprising new SNPs, new polypeptides derived from the natural EPO protein and comprising at least one mutation caused by the ...
|
|
WO/2002/083125A1 |
This invention relates to the use of a vitronectin receptor antagonist to inhibit adhesion formation.
|
|
WO/2002/079175A1 |
Compounds of formula (I): (I), and their salts, solvates, prodrugs, etc., wherein the substituents have the values mentioned herein, are Procollagen C-Proteinase (PCP) inhibitors and have utility in conditions mediated by PCP.
|
|
WO/2002/074056A2 |
The present invention relates to compounds of formulas (IA) and (IB): the preparation thereof, pharmaceutical formulations thereof, and their use in medicine as allosteric adenosine receptor modulators for uses including protection again...
|
|
WO/2002/074346A2 |
The present invention concerns a method for selectively targeting a medicinally-useful agent into cells in which a phospholipid scramblase (PLS) transport system is activated. The method comprises administering the agent, being a PLS-dep...
|
|
WO2000027868A9 |
The present invention provides rat connective tissue growth factor (CTGF), means for producing CTGF and therapeutic methods for using CTGF or derivatives thereof. The invention further provides methods for modulating the activity of CTGF...
|
|
WO/2002/072636A2 |
Methods are also provided for preparing stabilized formulations of whole antibody crystals or antibody fragment crystals using pharmaceutical ingredients or excipients and optionally encapsulating the crystals or crystal formulations in ...
|
|
WO/2002/070594A2 |
A method of preparing a collagen sponge comprises mixing air into a collagen gel, so as to obtain a collagen foam which is dried. From the dried product thereby obtained, collagen sponge is obtained by isolating parts of sponge with a ch...
|
|
WO/2002/068383A2 |
The present invention relates to biscarbodiimides, thiourea derivatives, urea derivatives, and cross-linked hyaluronan derivatives having at least one intramolecular disulfide bond, and methods of preparation thereof. The invention also ...
|
|
WO2000059515A9 |
Methods and products for inducing IL-2 secretion, inducing IL-10 secretion, activating T cells, suppressing IgG antibody response to specific antigen, promoting allograft survival, reducing postoperative surgical adhesion formation, and ...
|
